Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study

Eva Kulcsar-Jakab¹, Zsofia Petho², Zoltan Pap³, Edit Kalina¹, Roza Foldesi¹, Adam Balogh⁴, Peter Antal-Szalmas¹ and Harjit Pal Bhattoa¹*

Abstract

**Background:** The aim of the present study is to evaluate serum osteoprotegerin (OPG) and soluble receptor activator of nuclear factor κB ligand (sRANKL) levels in a randomly selected male cohort over 50 years of age and its association with cystatin C, a cysteine proteinase inhibitor that decreases formation of osteoclasts by interfering at a late stage of pre-osteoclast differentiation, apart from being a marker of renal function independent of gender, muscle mass and age; in addition to known predictors such as age, sex hormones, vitamin D, bone mineral density (BMD) and biochemical markers of bone turnover.

**Methods:** We determined serum OPG and sRANKL levels and examined its relationship with cystatin C, age, osteocalcin, C-terminal telopeptides of type-I collagen, procollagen type 1 amino-terminal propeptide, 25-hydroxyvitamin D, parathyroid hormone, total 17β-estradiol (E2), total testosterone and L1–L4 (LS) and femur neck (FN) BMD data available from 194 (age, range: 51–81 years) randomly selected ambulatory men belonging to the HunMen cohort.

**Results:** OPG correlated significantly with age (Spearman’s rho (r) = 0.359, p < 0.001), cystatin C (r = 0.298, p < 0.001), E2 (r = 0.160, p = 0.028) and free testosterone index (FTI) (r = −0.230, p = 0.001). Compared to the middle-aged (age: ≤ 59 years, n = 98), older men (age > 59 years, n = 96) had significantly higher serum OPG (4.6 pmol/L vs. 5.4 pmol/L; p < 0.001), and lower sRANKL (0.226 pmol/L vs. 0.167 pmol/L; p = 0.048) levels. The older men showed a significant correlation between serum OPG levels and cystatin C (Spearman’s rho = 0.322, p = 0.002), and E2 (Spearman’s rho = 0.211, p = 0.043). Including cystatin C and E2 in a regression model showed that cystatin C (standard regression coefficient (β) = 0.345; p = 0.002) was the only significant predictor of serum OPG levels in the older men.

**Conclusions:** The results of this study demonstrated that in addition to age (which was the stronger predictor), other modifiable factors such as cystatin C, FTI and E2 were also significant predictors of OPG, and that the association between cystatin C and OPG was more evident with increased age (older age group). As such, cystatin C is a significant predictor of OPG independently of age, FTI and E2.

Background

Osteoprotegerin (OPG) and receptor activator of nuclear factor-kB ligand (RANKL), two members of the tumor necrosis factor receptor super family, are essential in the regulation of bone resorption [1, 2]. OPG is a soluble decoy receptor, secreted by osteoblasts and other cell types, and competitively binds RANKL. RANKL is expressed primarily by osteoblasts and its receptor RANK is expressed in preosteoclasts and other cells of this lineage. When RANKL binds to RANK, osteoclastogenesis and bone resorption are induced. Thus, bone resorption may be prevented by OPG binding to RANKL [3]. In addition to being a key regulator of osteoclastogenesis, the OPG/ RANKL/RANK system is reported as being a significant mediator between factors such as estradiol, testosterone, parathyroid hormone, vitamin D, and bone turnover [3–6].

Data on OPG and RANKL levels in healthy men is accumulating [7–19]. Nonetheless, based on published...
data, it may well be generalized that the association between OPG/RANKL and its predictors is lacking consensus. Furthermore, the association of cystatin C with OPG and RANKL has only been limitedly investigated in the healthy, where no significant correlation was found [14]. Nonetheless, in-vitro studies have implied that cystatin C is a cysteine proteinase inhibitor that decreases osteoclastogenesis by interfering at a late stage of pre-osteoclast differentiation [20, 21]. Additionally, cystatin C possesses the advantage of being independent of gender, muscle mass and age; and consequently may qualify better than creatinine as a surrogate marker of renal function in investigating the role of decreased protein clearance as a potential cause of age-related OPG elevation [22]. The aim of the present study is to evaluate serum OPG and RANKL levels in a randomly selected male cohort over 50 years of age and its association with cystatin C, age, sex hormones, vitamin D, bone mineral density (BMD) and biochemical markers of bone turnover.

**Methods**

**Subjects**

The fasting serum samples (n = 194) for OPG and soluble RANKL (sRANKL) determinations belonged to participants in the HunMen cross-sectional, observational study [23]. Briefly the HunMen study was a local initiative to evaluate the bone health of randomly selected healthy men who confirmed to the inclusion and/or did not confirm to the exclusion criteria. Recruitment was between September 2009 and September 2010. Inclusion criteria were: over 50 years of age, male, ambulatory, community dwelling and generally regarded as healthy. Exclusion criteria were: known prevalent metabolic bone disease, liver or renal disease and use of medication influencing bone metabolism (excluding calcium and vitamin D supplementation). The study was approved by the ethics review board of the University of Debrecen, Hungary in compliance with the Declaration of Helsinki, and all subjects gave written informed consent.

**Study procedures**

Dual energy X-ray absorptiometry examination was performed using the LUNAR Prodigy (GE-Lunar Corp., Madison, Wisc., USA) densitometer. BMD was measured at L1-L4 lumbar spine (LS) and femur neck (FN). The coefficient of variation (CV) of the technique at our institute was 0.8 % using the anatomical spine phantom measured daily.

Serum total OPG and sRANKL were measured using enzyme immunoassays (Biomedica Gruppe, Biomedica Medizinprodukte GmbH & Co KG, Wein, Austria). The OPG assay, that detects monomeric dimeric and ligand bound OPG, uses a monoclonal mouse anti-OPG antibody as capture antibody and a biotin-labeled goat polyclonal antibody for detection. The sRANKL assay, that detects soluble, uncomplexed human RANKL, uses human recombinant OPG for capture and a biotin-labeled goat polyclonal antibody for detection. Plasma 25-hydroxyvitamin D (25-OH-D) was analyzed by high pressure liquid chromatography (HPLC) using a Jasco HPLC system (Jasco, Tokyo, Japan) and Bio-Rad reagent kit (Bio-Rad Laboratories, Hercules, CA, USA). Serum estradiol (E2), testosterone (T), sex hormone binding globulin (SHBG), parathyroid hormone (PTH), osteocalcin (OC), C-terminal telopeptides of type-I collagen (CTX), procollagen type I amino-terminal propeptide (PINP) were measured using electrochemiluminiscence immunoassay (Roche Diagnostics GmbH, Mannheim, Germany). The inter-assay CV was < 8 % for OPG (lower detection limit: 0.14 pmol/L, upper detection limit: 30 pmol/L), < 6 % for sRANKL (lower detection limit: 0.02 pmol/L, upper detection limit: 2 pmol/L), < 3.5 % for 25-OH-D (25-OH-D2 - lower detection limit: 13.1 nmol/L, upper detection limit: 606 nmol/L; 25-OH-D3 - lower detection limit: 16.5 nmol/L, upper detection limit: 624 nmol/L), < 7 % for E2 (lower detection limit: 0.018 nmol/L, upper detection limit: 15.78 nmol/L), < 9 % for T (lower detection limit: 0.087 nmol/L, upper detection limit: 52 nmol/L), < 6 % for SHBG (lower detection limit: 0.350 nmol/L, upper detection limit: 200 nmol/L), < 7 % for PTH (lower detection limit: 0.127 pmol/L, upper detection limit: 530 pmol/L), < 4 % for OC (lower detection limit: 0.5 µg/L, upper detection limit: 300 µg/L), < 7 % for CTX (lower detection limit: 0.010 µg/L, upper detection limit: 6 µg/L) and < 6 % for PINP (lower detection limit: 5 µg/L, upper detection limit: 1200 µg/L).

Plasma cystatin C was measured using particle-enhanced nephelometric immunoassay (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany), its inter-assay CV was < 4 % (lower detection limit: 0.05 mg/L, upper detection limit: 7.58 mg/L). Creatinine was measured using the Creatinine Jaffé 2nd generation (compensated) test on the cobas c 111 system (Roche Diagnostics GmbH, Mannheim, Germany). The free estradiol index (FEI) and free testosterone index (FTI) was calculated as the total 17β-estradiol to SHBG ratio and total testosterone to SHBG ratio, respectively. The 4-variable modification of diet in renal disease (MDRD) study equation was used for calculating eGFR [24]. Additionally, eGFR was also calculated using the chronic kidney disease-epidemiology collaboration (CKD-EPI) cystatin C and CKD-EPI creatinine-cystatin C equations [25, 26].

**Statistical analysis**

Kolmogorov-Smirnov test was used for the evaluation of the normality of the data. Most parameters were non-normally distributed; therefore analyses were performed by Mann–Whitney U test. The Spearman’s rho was calculated for correlation analysis. Associations were tested
using linear regression analysis after log transformation of not normal variables. Additionally, to reduce the conounding effect of age, the median age was used to form two subgroups. A value of \( p < 0.05 \) was considered statistically significant. All analyses were performed with the SPSS Statistics software, version 19.0 (IBM Corps., Armonk, NY, USA).

**Results**

In the HunMen study, a total of 229 randomly selected volunteers agreed to participate. Volunteers not confirming to the inclusion and/or confirming to the exclusion criteria \( (n = 23) \) were excluded from the study’s final statistical analysis. The HunMen study was not designed primarily for the aim of this study, and only 194 samples were available for serum OPG and sRANKL determination from a total of 206 participants. The general characteristics of the subjects \( (n = 194) \) are presented in Table 1.

OPG significantly correlated with age, cystatin C, E2 and FTI (Table 2).

Furthermore, Cystatin C correlated with age (Spearman’s \( \rho = 0.377, \ p < 0.001 \)), creatinine (Spearman’s \( \rho = 0.487, \ p < 0.001 \)), MDRD eGFR (Spearman’s \( \rho = -0.524, \ p < 0.001 \)), E2 (Spearman’s \( \rho = 0.222, \ p = 0.003 \)), PINP (Spearman’s \( \rho = 0.151, \ p = 0.040 \)) and OPG (Spearman’s \( \rho = 0.298, \ p < 0.001 \)). Although OPG did not correlate with serum creatinine or MDRD eGFR, it did show a significant correlation with cystatin C-eGFR, and cystatin C and creatinine-eGFR.

Multivariate linear regression analysis was carried out to determine the statistically significant predictors of serum OPG levels. Including age, cystatin C, FTI and E2 in a regression model showed that age, cystatin C, FTI and E2 were significant predictors of serum osteoprotegerin levels (Table 3).

In order to reduce the confounding effect of age, using the median age of 59 years, the study population was divided into a middle-aged (those \( \leq 59 \) years of age, \( n = 98 \)) and an older (those \( > 59 \) years of age, \( n = 96 \)) sub-group. Compared to the middle-aged (age \( \leq 59 \) years, \( n = 98 \)), older men had significantly higher serum OPG and significantly lower RANKL levels and RANKL/OPG ratios (Table 1). The middle-aged individuals showed no significant correlation between serum OPG and sRANKL levels and the other studied parameters (Table 2). The older men showed a significant correlation between serum OPG levels and cystatin C. Including cystatin C and E2 in a regression model showed that cystatin C (standard regression coefficient \( (\beta) = 0.345; \ p = 0.002 \)) was the only significant predictor of serum OPG levels in the older men.

There was no statistically significant difference in the group with non-detecatable (<0.02 pmol/L, \( n = 74 \)) sRANKL

**Table 1 Subject characteristics**

|                      | All men \( (n = 194) \) | Middle-aged men \( (\leq 59 \) years of age, \( n = 98) \) | Older men \( (> 59 \) years of age, \( n = 96) \) |
|----------------------|------------------------|-----------------------------------------------------|-------------------------------------------------|
| Age, years (mean, range) | 60.4 (51–81)          | 55.6 (51–59)                                        | 65.4 (60–81)                                     |
| Body mass index, kg/m\(^2\) (mean, range) | 29.2 (17.3–41.7)      | 28.9 (18–38.5)                                      | 29.5 (17.3–41.7)                                |
| Osteoprotegerin, pmol/L (mean, range) | 5.0 (2.2–10.1)        | 4.6 (2.2–7.7)**                                     | 5.4 (3.0–10.1)**                                 |
| sRANKL, pmol/L (mean, range) | 0.197 (0.020–0.875)    | 0.226 (0.026–0.875)**                               | 0.167 (0.020–0.795)**                            |
| PINP, pmol/L (mean, range) | 0.043 (0.003–0.256)    | 0.053 (0.006–0.256)**                               | 0.033 (0.003–0.176)**                            |
| Total CM-I collagen, nmol/L (mean, range) | 0.09 (0.02–0.19)      | 0.09 (0.03–0.19)                                    | 0.08 (0.02–0.15)                                |
| Total osteocalcin, μg/L (mean, range) | 12.8 (0.3–41.7)       | 13.1 (2.7–41.7)                                     | 12.4 (3.0–32.1)                                 |
| total hormone binding globulin, mmol/L (mean, range) | 40.8 (12.3–196.2)    | 40.7 (12.7–196.2)                                   | 40.9 (12.3–115.5)                               |
| Free Estradiol Index (mean, range) | 0.0026 (0–0.009)      | 0.0026 (0.001–0.007)                                | 0.0025 (0–0.009)                                |
| Free testosterone Index (mean, range) | 0.3398 (0.005–0.743)  | 0.354 (0.081–0.704)**                               | 0.325 (0.005–0.743)**                           |
| PTH, pmol/L (mean, range) | 4.2 (1.1–10.2)        | 4.2 (1.1–10.2)                                      | 4.3 (1.6–8.3)                                    |
| 25-hydroxy-vitamin D, nmol/L (mean, range) | 73.1 (11–185)         | 72.1 (11–137)                                       | 74.0 (14–185)                                    |
| Osteocalcin, μg/L (mean, range) | 14.6 (5–35)          | 15.2 (5–33)                                         | 14.0 (6–35)                                      |
| Total C-terminal telopeptides of type-I collagen, μg/L (mean, range) | 0.22 (0.01–0.77)   | 0.24 (0.01–0.77)                                    | 0.20 (0.04–0.70)                                |
| PINP, μg/L (mean, range) | 38.3 (10.5–98.6)      | 39.2 (10.5–98.6)                                    | 37.3 (13.1–81.3)                                |
| Cystatin C, mg/L (mean, range) | 0.697 (0.381–1.150)  | 0.657 (0.381–1.060)**                               | 0.736 (0.485–1.150)**                            |
| L1-L4 bone mineral density, gm/cm\(^2\) (mean ± SD) | 1.172 ± 0.185        | 1.148 ± 0.167                                       | 1.197 ± 0.199                                    |
| Femur neck bone mineral density, gm/cm\(^2\) (mean ± SD) | 0.970 ± 0.137        | 0.980 ± 0.131                                       | 0.960 ± 0.142                                    |

sRANKL Soluble receptor activator of nuclear factor –κB ligand, PINP Total procollagen type I amino-terminal propeptide

* * * **p < 0.001, ***p < 0.005, ****p < 0.007 and *****p < 0.004 between middle-aged and older men
concentrations as compared to those with detectable (≥0.02 pmol/L, \( n = 120 \)) sRANKL concentrations in the studied parameters, except for LS (1.190 (0.810-1.892) vs. 1.143 (0.749-1.855) gm/cm\(^2\); \( p = 0.043 \)) and FN (0.984 (0.646-1.281) vs. 0.949 (0.602-1.331) gm/cm\(^2\); \( p = 0.049 \)) BMD. As such, LS and FN BMD is significantly lower in those with undetectable sRANKL levels.

There was no difference in OPG, sRANKL and sRANKL/OPG ratio upon comparing the vitamin D sufficient (25-OH-D ≥ 75 nmol/L) with the vitamin D insufficient (25-OH-D < 75 nmol/L) individuals.

**Discussion**

Our results demonstrate that serum OPG levels increase and sRANKL/OPG ratio decreases with age in healthy men over 50 years of age. With regards to the relationship of OPG with age, our findings are in tune with those reported by others (7–10,12,14-19). As enumerated in Table 4, among the various predictors studied, perhaps the positive correlation of OPG with age is the only finding showing consensus in the different studies to date. The only exception with this regards is the non-significant finding by Oh et al., where the lack of correlation may be due to the limited number of cases studied (\( n = 80 \)) and a relatively lower age maximum of the study population (i.e., 70 years).

With regards to the correlation of OPG with BMD and biochemical markers of bone turnover, as per the results of the studies published to date, statistically significant positive, negative and non-significant findings have been presented (see Table 4). Our finding of non-significance only contributes to the need for further studies. Knowing that OPG messenger ribonucleic acid (mRNA) is expressed in a variety of tissues, including lung, kidney and heart, multiple

---

**Table 2** Spearman’s correlation analysis between serum osteoprotegerin and the studied variables

| All men \((n = 194)\) | Middle-aged men \((\leq 59 \text{ years of age}, n = 98)\) | Older men \((>59 \text{ years of age}, n = 96)\) |
|------------------------|---------------------------------|---------------------------------|
|                         | \( r \) | \( p \) | \( r \) | \( p \) | \( r \) | \( p \) |
| Age                    | 0.359  | <0.001 | 0.165  | 0.105  | 0.050  | 0.631  |
| Body mass index        | 0.031  | 0.672  | 0.057  | 0.580  | -0.036 | 0.725  |
| sRANKL                 | -0.034 | 0.713  | -0.019 | 0.885  | -0.038 | 0.774  |
| sRANKL/OPG ratio       | -0.234 | 0.010  | -0.204 | 0.116  | -0.199 | 0.131  |
| Total 17-β-Estradiol   | 0.160  | 0.028  | 0.164  | 0.110  | 0.211  | 0.043  |
| Total testosterone     | -0.025 | 0.729  | 0.106  | 0.302  | -0.064 | 0.540  |
| Sex hormone binding globulin | 0.070  | 0.342  | 0.199  | 0.052  | 0.060  | 0.568  |
| Free Estradiol Index   | -0.072 | 0.323  | -0.084 | 0.414  | 0.048  | 0.648  |
| Free testosterone Index| -0.230 | 0.001  | -0.142 | 0.167  | -0.169 | 0.106  |
| Parathyroid hormone    | -0.076 | 0.300  | -0.172 | 0.093  | -0.009 | 0.990  |
| 25-hydroxy-vitamin D   | -0.123 | 0.091  | -0.115 | 0.085  | -0.030 | 0.774  |
| Osteocalcin            | -0.102 | 0.161  | -0.037 | 0.717  | -0.040 | 0.706  |
| C-terminal telopeptides of type-I collagen | -0.100 | 0.171  | -0.095 | 0.358  | -0.053 | 0.611  |
| PINP                   | -0.043 | 0.553  | -0.006 | 0.951  | -0.044 | 0.667  |
| L1-L4 bone mineral density | 0.026  | 0.716  | -0.041 | 0.689  | 0.010  | 0.923  |
| Femur neck bone mineral density | -0.074 | 0.307  | -0.071 | 0.485  | -0.001 | 0.995  |
| Cystatin C             | 0.298  | <0.001 | 0.022  | 0.832  | 0.322  | 0.002  |
| Creatinine             | 0.038  | 0.618  | -0.085 | 0.415  | 0.132  | 0.239  |
| MDRD-eGFR              | -0.071 | 0.351  | 0.083  | 0.428  | -0.142 | 0.207  |
| Cystatin C-eGFR        | -0.343 | <0.001 | -0.031 | 0.766  | -0.335 | 0.001  |
| Cystatin C and creatinine-eGFR | -0.231 | 0.003  | 0.023  | 0.834  | -0.262 | 0.020  |

sRANKL Soluble receptor activator of nuclear factor – κB ligand, PINP Total procollagen type 1 amino-terminal propeptide

---

**Table 3** Predictors of osteoprotegerin using multiple regression analysis

|                        | Osteoprotegerin |
|------------------------|-----------------|
| Age                    | \( 0.232 \)     | \( 0.002 \) |
| Total 17-β-Estradiol   | \( 0.166 \)     | \( 0.021 \) |
| Free testosterone Index| \( -0.178 \)    | \( 0.012 \) |
| Cystatin C             | \( 0.182 \)     | \( 0.015 \) |
tissues contribute together to circulating OPG, as such measurement of OPG levels in the bone microenvironment is most desirable [27].

Our finding of statistically significant positive correlation between E2 with OPG, along with those reported by Schulz et al. and Indridason et al., supports the finding that E2 increases OPG mRNA steady state levels and protein production in a human estrogen-responsive osteoblastic cell line [4]. Furthermore, Khosla et al. have demonstrated that estrogen treatment increases OPG levels in adult men [9]. Our finding of negative correlation between testosterone and OPG supports two and disagrees with another 2 previous studies [5, 7, 8, 14]. Nonetheless, the negative correlation supports the finding by Khosla et al. where it

Table 4 Literature data on correlation coefficients (with p values) between serum osteoprotegerin levels in men and the studied parameters

| Authors            | Age          | BMD         | T   | E2   | FEI   | FTI   | PTH  | 25-OH-D | Creatinine | Bone markers |
|--------------------|--------------|-------------|-----|------|-------|-------|------|---------|------------|-------------|
| Szulc et al. [7]   | r = 0.41     | n.s.        | n.s.| n.s. | *r = 0.18* | *r = 0.31* | r = -0.23 | n.s.     | *r = -0.20* | p < 0.01    |
|                   | p = 0.0001   |             |     |      | p < 0.02 | p = 0.0001 | p < 0.01 |         |           |             |
| Khosla et al. [8]  | r = 0.39     | *r = -0.17* | r = -0.16 | n.s. | *r = -0.27* | -    | -    | -       | p < 0.001  |             |
|                   | p < 0.001    |             |     |      | p < 0.05 | p < 0.05 |         |         |           |             |
| Khosla et al. [9]  | -            |             |     |      | -    | -    | -    | -       | -          |             |
| Kudlacek et al. [10]| p < 0.05    | n.s.        | r = 0.1 | -    | -    | -    | r = -0.17 | n.s.     | -          |             |
|                   | p < 0.05     |             |     |      | -    | -    | -    |         |           |             |
| Trofimov et al. [12]| r = 0.42    | n.s.        | n.s.| n.s. | -    | -    | -    | -       | -          |             |
|                   | p < 0.001    |             |     |      | -    | -    | -    | -       | -          |             |
| Oh et al. [13]     | n.s.         | i r = -0.259 | n.s. | r = -0.319 | -    | -    | -    | -       | -          | i r = -0.25 |
|                   | p = 0.020    |             |     |      | p = -0.004 |         |         |         |           |             |
| Indridason et al. [14]| p < 0.05  | r = -0.13   | p ≤ 0.05 | -    | -    | i r = 0.15 | i r = 0.09 | n.s.     | i r = -0.09 | p ≤ 0.05   |
|                   |             |             |     |      | p ≤ 0.05 | p ≤ 0.05 |         |         |           |             |
| Mazzotti et al. [15]| r = 0.37    | -            | -   | -    | -    | -    | -    | -       | -          | -           |
|                   | p = 0.002    |             |     |      | -    | -    | -    | -       | -          |             |
| Stern et al. [16]  | r = 0.552    | *p < 0.05*  | -   | -    | -    | -    | -    | -       | -          |             |
|                   | p < 0.001    |             |     |      | -    | -    | -    | -       | -          |             |
| Samelson et al. [17]| i p < 0.05  | -            | -   | -    | -    | -    | -    | -       | -          | -           |
|                   |             |             |     |      | -    | -    | -    | -       | -          |             |
| Jorgensen et al. [18]| r = 0.52 | *p = 0.001* | -   | -    | -    | -    | -    | -       | -          | -           |
|                   | p < 0.001    |             |     |      | -    | -    | -    | -       | -          |             |
| Szulc et al. [19]  | -            | *r = -0.28* | -   | -    | -    | -    | -    | -       | -          | -           |
|                   |             |             |     |      | p < 0.001 |         |         |         |           |             |

This study

| r = 0.359 | n.s. | n.s. | r = 0.16 | n.s. | r = -0.23 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| p < 0.001 | p = 0.028 |         | p = 0.001 |         |         |       |     |     |     |     |     |

BMD bone mineral density, T testosterone, E2 β-estradiol, FEI free estradiol index, FTI free testosterone index, PTH parathyroid hormone, 25-OH-D 25-hydroxyvitamin D

Statistically significant positive correlation, but r value is not mentioned, n.s. n.s. n.s.
was demonstrated in vivo that testosterone therapy resulted in lower OPG levels [9].

Our finding of non-correlation of age with sRANKL is in accordance with that reported earlier [11–13, 15, 16, 18]. Upon bivariate analysis we found no correlation between sRANKL and BMD, this finding is in agreement with that of Trofimov et al. and Oh et al., but in disagreement with the findings of Stern et al., who reported an inverse association between RANKL and BMD [12, 13, 16]. Nonetheless, we observed statistically higher FN and LS BMD in those with detectable (higher) sRANKL levels, this finding, at least in part, may explain the low risk of non-traumatic fracture in participants in the highest tertile of RANKL in the study by Schett et al. [11]. It needs to be pointed out that Schett et al. found no relationship between sRANKL and bone ultrasound data and they did not carry out BMD measurements in their study population [11].

Adding to the controversy is the finding by Jørgensen et al., where they found no difference in BMD between those with detectable versus non-detectable sRANKL levels [18]. Although the present generation of sRANKL immunoassays has a better lower detection limit than its predecessors, methodology with improved detection limits are most desired. Probably introduction of more sensitive immunoassays may help quantify undetectable sRANKL levels and perhaps may help explore relationships between those with low sRANKL and its known predictors.

As far, the one study that studied the relationship of sRANKL/OPG ratio with age found no significance with this regards, in contrast to this our study reports a negative correlation between the ratio and age. This finding certainly needs validation by others.

Although it is suggested that PTH has a suppressive effect on OPG production, the present study did not find any correlation between PTH and OPG [28, 29]. Our results are in agreement with those of Indridason et al. and in contrast to those of Szulc et al. and Kudlacek et al. [7, 10, 14].

In contrast to the finding that 1,25 dihydroxyvitamin D stimulates OPG production, in vivo studies in healthy men, including the present study, have not found any correlation between 25-OH-D, an index of body vitamin D status, and OPG [7, 10, 14, 30, 31].

In summary, the non-agreement between findings from different studies may be explained, at least partially, by the different assay methodology, in some cases the use of frozen samples more than a decade old, the different recruitment criteria used in the selection of the cohort, the size of the study sample and perhaps the age composition of the cohorts studied.

The role of decreased protein clearance as a potential cause of age-related OPG elevation has been considered in a few previous studies [15, 17, 19]. Mazzioti et al. found a significant positive correlation between creatinine and OPG, and Samelson et al. found that with increasing quartiles of OPG the GFR decreased significantly [15, 17]. This finding is in contrast to the results of Szulc et al., where no correlation was found between OPG and creatinine [19]. Our findings show that there is no correlation between OPG and eGFR, when the MDRD equation is used, but there is a significant negative correlation using the CKD-EPI cystatin C and the CKD creatinine-cystatin C equations. This finding may illustrate the importance of the type of equation used to calculate eGFR. Nonetheless, the combined creatinine-cystatin C equation is considered to perform better than equations based on either of these markers alone [25, 26]. We found a strong positive correlation between OPG and cystatin C. Our positive finding is in contrast to that of Indridason et al., where no such correlation was found [14]. Although the assay methodology used by Indridason et al. is not the one used by us, this difference alone does not explain the difference in the observations of the two studies. Nonetheless, serum OPG has been shown to correlate positively in male patients with chronic renal failure [32].

Although the study participants were members of a well-defined healthy cohort randomly selected from the population, there are limitations to our study. The HunMen study was not designed primarily for the aim of this manuscript, and only 194 samples were available for serum OPG and sRANKL determination from a total of 206 participants [20]. In addition, we were not in a position to study the effects of bioavailable (free) sex hormones on OPG, instead we used calculated free sex hormone indices to carry out the different statistical analysis. Although the mechanism of the effect, as a renal marker or inhibitor of osteoclastogenesis, of cystatin C on OPG levels cannot be elucidated by the findings of the present study, we have found that it is a significant predictor of serum OPG levels. These findings need verification and further studies are necessary.

The present study confirms to the STROBE Statement, a checklist of items that should be included in reports of observational studies has been provided as Additional file 1 [33].

**Conclusion**

The present study demonstrated that in addition to age, the stronger predictor, other adjustable factors such as cystatin C, FTI and E2 were also significant predictors of OPG. Furthermore, the association between cystatin C and OPG was more evident with increased age. In conclusion, cystatin C is a significant predictor of OPG independently of age, FTI and E2.
Additional file

Additional file 1: STROBE Statement—checklist of items that should be included in reports of observational studies.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Study Design: AB, PAS, HPB. Study conduct: EKJ, ZsP, AB, PAS, HPB. Data collection: EKJ, ZsP, AB, HPB. Data interpretation: EKJ, ZsP, ZoP, AB, PAS, HPB. Drafting manuscript: EKJ, ZsP, HPB. Revising manuscript content: ZoP, HPB. Approving final version of manuscript: EKJ, ZsP, ZoP, ER, AB, PAS, HPB. HPB takes responsibility for integrity of the data analysis.

Acknowledgements
This work is supported by the OTKA 105073 research grant (HPB) and the TAMOP 4.2.2.A-11/1-KONV-2012-0025 project (PAS), which is implemented through the New Hungary Development Plan, co-financed by the European Social Fund.

Received: 4 February 2015 Accepted: 14 August 2015
Published online: 28 August 2015

References
1. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142:5050–5.
2. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504–8.
3. Vega D, Maalouf NM, Sakhaee K. Clinical review: the role of receptor activator of nuclear factor-kappaB ligand (RANKL)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007;92:4514–21.
4. Hofbauer LC, Khosla S, Dunstan CR, Lacay DL, Spelsberg TC, Riggs BL. Estrogen and progesterone stimulation of gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999;140:367–70.
5. Hofbauer LC, Hicok KC, Chen D, Khosla S. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur J Endocrinol. 2002;147:269–73.
6. Hofbauer LC, Heufelder AE. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab. 2000;85:2355–63.
7. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab. 2001;86:3162–5.
8. Khosla S, Arrighi HM, Melton III LJ, Atkinson EJ, O’Fallon WM, Dunstan C, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int. 2002;13:394–9.
9. Khosla S, Atkinson EJ, Dunstan CR, O’Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab. 2002;87:1550–4.
10. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone. 2003;32:681–6.
11. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, et al. Soluble RANKL and risk of nonunions in fracture. JAMA. 2004;291:1108–13.
12. Trofimov S, Pantulalia J, Kobylanski E, Lichtvist G. Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophase-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol. 2004;150:305–11.
13. Oh KW, Rhee EJ, Lee WT, Kim SW, Baek KH, Kang MI, et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol. 2005;62:92–8.
14. Indridason OS, Franzen L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int. 2005;16:417–23.
15. Mazzotti G, Amato G, Sonvico F, Pisicopo M, Rizzo MR, Laib E, et al. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. Eur J Endocrinol. 2006;154:73–7.
16. Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. The six-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB ligand with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol. 2007;156:555–62.
17. Samelson EJ, Broe KE, Demiesie S, Beck TJ, Karakik D, Kathiresan S, et al. Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. J Clin Endocrinol Metab. 2008;93:1789–95.
18. Jorgensen L, Vik A, Emaas N, Broc J, Hansen JB, Mathiesen E, et al. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study. Osteoporos Int. 2010;21:931–8.
19. Suzuki P, Hava G, Bouthillette L, Villaphiou N, Schroppet M, Chapurlat R, et al. Cortical bone status is associated with serum osteoprotegerin concentration in men: the STRAMBO study. J Clin Endocrinol Metab. 2011;96:2216–26.
20. Brage M, Lie A, Ransjo M, Kaspzykowski F, Kaspzykowska R, Abrahamson M, et al. Osteoclastogenesis is decreased by cytokine proteinase inhibitors. Bone. 2004;34:412–24.
21. Brage M, Abrahamson M, Lindström V, Grubb A, Lerner UH. Different cytokine proteinases involved in bone resorption and osteoclast formation. Calciif Tissue Int. 2005;76:439–47.
22. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function – a review. Clin Chem Lab Med. 1999;37:389–95.
23. Bhuttao HP, Nagy E, More C, Kappelmayer J, Balogh A, Kalina E, et al. Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age. The HunMen Study. Osteoporos Int. 2013;24:719–86.
24. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:427–54.
25. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9.
26. Teo BW, Sabanayagam C, Liao J, Toh QC, Saw S, Wong TY, et al. Comparison of CKD-EPI cystatin C and creatinine glomerular filtration rate estimation equations in Asian Indians. Int J Nephrol. 2014;2014:672649.
27. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;90:309–19.
28. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, et al. In vivo demonstration that parathyroid hormone 1–38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res. 2000;15:863–71.
29. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology. 1999;140:552–61.
30. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate CKD-EPI cystatin C and creatinine glomerular filtration rate estimation equations in Asian Indians. Int J Nephrol. 2014;2014:672649.
31. Murakami T, Yamamoto M, Ono K, Nishikawa M, Nagata N, Motoyoshi K, et al. Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun. 1998;252:747–52.
32. Shaarawy M, Fathy SA, Mehany NL, Hindy OW. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure. Clin Chem Lab Med. 2007;45:1498–503.
33. www.strobe-statement.org. Accessed 25 July 2015.